CD30

TNF receptor superfamily member 8
معین‌کننده‌ها
نام‌های دیگر	CD30L receptorlymphocyte activation antigen CD30tumor necrosis factor receptor superfamily member 8cytokine receptor CD30Ki-1 antigenTNFRSF8
شناسه‌های بیرونی	GeneCards:
الگوی گسترش RNA
	More reference expression data
هم‌ساخت‌شناسی
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	ویکی‌داده
مشاهده/ویرایش Human

مجموعهٔ تمایزی ۳۰ (انگلیسی: Cluster of Differentiation 30‎) یا به‌اختصار «CD30» که با نام «TNFRSF8» هم شناخته می‌شود، پروتئینی از خانوادهٔ بزرگ فاکتور نکروز تومور و همچنین یک نشانگر تومور است.

این پروتئین بر روی سطح لنفوسیت‌های تی و لنفوسیت‌های بی فعال بیان می‌شود.

این مولکول پروتئینی با سرطان «لنفوم آناپلاستیک سلول بزرگ» (ALCL) در ارتباط است. این پروتئین در «کارسینوم اِمبریونال» (و نه در «سمینوما») دیده می‌شود و می‌توان از آن به‌عنوان یک نشانگر تومور در افتراق تومورهای سلول زایا (Germ cell tumor) استفاده کرد.[1] CD30 و CD15 در سلول‌های رید-اشترنبرگ لنفوم هاجکین هم بیان می‌شوند.[2]

منابع

Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (به Chinese). 34 (11): 711–5. PMID 16536313.
Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.

مشارکت‌کنندگان ویکی‌پدیا. «CD30». در دانشنامهٔ ویکی‌پدیای انگلیسی، بازبینی‌شده در ۱۸ دسامبر ۲۰۱۷.

بیشتر بخوانید

Schneider C, Hübinger G (Jul 2002). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family". Leukemia & Lymphoma. 43 (7): 1355–66. doi:10.1080/10428190290033288. PMID 12389614.
Horie R, Higashihara M, Watanabe T (Jan 2003). "Hodgkin's lymphoma and CD30 signal transduction". International Journal of Hematology. 77 (1): 37–47. doi:10.1007/BF02982601. PMID 12568298.
Tarkowski M (Jul 2003). "Expression and a role of CD30 in regulation of T-cell activity". Current Opinion in Hematology. 10 (4): 267–71. doi:10.1097/00062752-200307000-00003. PMID 12799531.
Granados S, Hwang ST (Jun 2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases". The Journal of Investigative Dermatology. 122 (6): 1345–7. doi:10.1111/j.0022-202X.2004.22616.x. PMID 15175022.
Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (Feb 1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell. 68 (3): 421–7. doi:10.1016/0092-8674(92)90180-K. PMID 1310894.
Fonatsch C, Latza U, Dürkop H, Rieder H, Stein H (Nov 1992). "Assignment of the human CD30 (Ki-1) gene to 1p36". Genomics. 14 (3): 825–6. doi:10.1016/S0888-7543(05)80203-4. PMID 1330892.
Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay". European Journal of Immunology. 19 (1): 157–62. doi:10.1002/eji.1830190125. PMID 2537734.
Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl V (Oct 1982). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". International Journal of Cancer. 30 (4): 445–59. doi:10.1002/ijc.2910300411. PMID 6754630.
Jung W, Krueger S, Renner C, Gause A, Sahin U, Trümper L, Pfreundschuh M (Dec 1994). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology. 31 (17): 1329–34. doi:10.1016/0161-5890(94)90051-5. PMID 7527901.
Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S (Jun 1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3". Oncogene. 9 (6): 1567–74. PMID 8183550.
Lee SY, Park CG, Choi Y (Feb 1996). "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors". The Journal of Experimental Medicine. 183 (2): 669–74. doi:10.1084/jem.183.2.669. PMC 2192463. PMID 8627180.
Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB (May 1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". The Journal of Biological Chemistry. 271 (22): 12852–8. doi:10.1074/jbc.271.22.12852. PMID 8662842.
Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T (Oct 1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages". Blood. 88 (7): 2422–32. PMID 8839832.
Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID 8999898.
Lee SY, Lee SY, Choi Y (Apr 1997). "TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation". The Journal of Experimental Medicine. 185 (7): 1275–85. doi:10.1084/jem.185.7.1275. PMC 2196258. PMID 9104814.
Boucher LM, Marengère LE, Lu Y, Thukral S, Mak TW (Apr 1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily". Biochemical and Biophysical Research Communications. 233 (3): 592–600. doi:10.1006/bbrc.1997.6509. PMID 9168896.
Duckett CS, Thompson CB (Nov 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development. 11 (21): 2810–21. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251.
Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J (Jan 1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)". Gene. 207 (2): 135–40. doi:10.1016/S0378-1119(97)00616-1. PMID 9511754.
Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR (Mar 1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells". Nature. 398 (6725): 341–4. doi:10.1038/18692. PMID 10192335.

پیوند به بیرون

CD30 Antigens در سرعنوان‌های موضوعی پزشکی (MeSH) در کتابخانهٔ ملی پزشکی ایالات متحدهٔ آمریکا
مکان ژنوم TNFRSF8 انسانی و صفحهٔ جزئیات ژنی TNFRSF8 در سامانه جستجوی بانک ژنی دانشگاه کالیفرنیا، سانتا کروز.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (به Chinese). 34 (11): 711–5. PMID 16536313.

[2] Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.